New National Survey Finds Nearly Half of US Adults Admit to Not Washing Their Hands at Key Moments
2025 State of Handwashing Report by the National Foundation for Infectious Diseases finds that many US adults forget or choose not to wash their hands at key times when germs can easily spread
1 out of 5 (20%) admit to not washing their hands, even though handwashing can help prevent approximately 80% of infectious diseases
BETHESDA, Md., May 5, 2025 /PRNewswire/ -- Today, on World Hand Hygiene Day, the National Foundation for Infectious Diseases (NFID) is launching the Hands In For Handwashing campaign to raise awareness about the importance of handwashing to help stop the spread of infectious diseases. The campaign includes the 2025 NFID State of Handwashing Report, based on a new national survey of US adult handwashing knowledge and behaviors.
The report offers unique insights into where, when, and why US adults are most likely to wash their hands, and when they forget or choose not to do so. Following the worst influenza (flu) season in more than a decade and several norovirus outbreaks across the US, the NFID report reveals that while US adults say they know how to wash their hands properly, their habits often suggest otherwise.
Key survey findings:
'Given the importance of handwashing in infectious disease prevention, the stakes are high—improving hand hygiene can help improve health for all,' said NFID Medical Director Robert H. Hopkins, Jr., MD. 'While handwashing is an important strategy for disease prevention, and should be complementary to vaccination, it is a critical and often overlooked tool.' Estimates show that if everyone routinely washed their hands, about 1 million lives could be saved around the world each year.
According to the survey, 55% of US adults wash their hands primarily to stay healthy and avoid getting sick. In addition, 68% of respondents said that avoiding spreading germs to others was among their top 3 reasons for handwashing, showing concern for protecting others in the community.
'Proper handwashing puts the power of health in our own hands,' said NFID Immediate Past-President Patricia A. Stinchfield, RN, MS, CPNP. 'Handwashing is an easy and effective way to prioritize your health and the health of those around you.'
For some, handwashing is a seasonal behavior–1 in 4 (26%) respondents reported washing their hands more frequently in the fall and winter, even though germs can spread throughout the year. The survey also found that 33% of respondents report washing their hands more now than they did during the COVID-19 pandemic.
As part of the campaign, NFID is also hitting the road with a Clean Hands Caravan, a mobile handwashing station to make it easier for people to wash their hands in places where germs can spread.
'The caravan was created to make handwashing accessible and visible during key moments in everyday life when it is important to wash hands,' said NFID Chief Executive Officer Marla Dalton, PE, CAE. 'We wanted to grab people's attention with vibrant colors, eye-catching graphics, and memorable slogans to bring some excitement to an important but sometimes overlooked habit taught in kindergarten—washing your hands.'
The Clean Hands Caravan tour launched at the Washington Spirit soccer game in Washington, DC on May 2, 2025. Additional tour stops include the World Barbeque Cooking Contest in Memphis, TN, from May 14-17, 2025, and the Atlanta Jazz Festival in Atlanta, GA, from May 24-26, 2025. 'NFID encourages everyone to wash their hands to help stop the spread of infectious diseases, and we encourage organizations to join the Hands In For Handwashing movement to support healthier lives for all,' Dalton said.
For more information about the 2025 NFID State of Handwashing report, and to access handwashing resources throughout the year, visit: www.nfid.org/handwashing
About the National Foundation for Infectious Diseases
Founded in 1973, the National Foundation for Infectious Diseases (NFID) is a non-profit 501(c)(3) organization dedicated to educating and engaging the public, communities, and healthcare professionals about infectious diseases across the lifespan. NFID has a 4-star rating from Charity Navigator and has earned a Platinum transparency seal from Candid/GuideStar. For more information, visit www.nfid.org.
About the Survey
The survey was funded by NFID and conducted by NORC at the University of Chicago as part of the AmeriSpeak Omnibus®, a monthly survey using the NORC probability-based panel designed to be representative of the US household population. The US survey received responses from 3,587 respondents from all 50 states and the District of Columbia via online and telephone interviews using landlines and cell phones. Data was collected in November and December 2024 and March 2025. The margin of sampling error is ±2 percentage points for all respondents.
Contact: Ryan Horey, [email protected]
View original content to download multimedia: https://www.prnewswire.com/news-releases/new-national-survey-finds-nearly-half-of-us-adults-admit-to-not-washing-their-hands-at-key-moments-302445548.html
SOURCE National Foundation for Infectious Diseases
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
10 minutes ago
- Medscape
Radiology Workforce Shortages Impacting Cancer Care
A chronic shortage of radiologists and oncologists is putting patients in the UK at risk, a new report found. The annual workforce census by the Royal College of Radiologists (RCR) warned that the safe delivery of NHS cancer care is becoming 'increasingly impossible' due to an escalating shortfall of doctors coupled with rising demand for care. In 2024, the UK had a 29% shortfall of clinical radiologists, with regional gaps ranging from 25% in Scotland to 32% in Wales. The workforce grew by 4.7% that year — less than in 2023, when it increased by 6.3%. The college forecasts the radiologist shortfall will reach 39% by 2029. Oncology Under Strain Clinical oncologists are also in short supply, with a current 15% gap expected to rise to 19% by 2029. This is despite a 5.4% increase in the workforce in 2024—the strongest growth since 2018. The RCR reported that 23% of cancer centres were experiencing recruitment freezes, making it harder to meet growing demand. Demand Continues to Outpace Capacity The shortages threaten the government's plans to cut waiting times and improve cancer outcomes. In 2024, demand for computerised tomography (CT) and magnetic resonance imaging (MRI) grew by 8%, but workforce growth did not keep pace. Every radiology leader surveyed last year reported delays to diagnostic scans caused by staff shortages. Nine in 10 radiology team leaders reported that patients were waiting longer to start treatment, while seven in 10 expressed concern that staff shortages were putting patient safety at risk – down slightly from 85% in 2023. Chronic problems such as workforce shortages, reporting backlogs, and staff vacancies remain too high, according to Dr Robin Proctor, the RCR's m edical director responsible for professional practice and clinical radiology. Consultants Leaving Earlier Staff retention is worsening, with experienced consultants leaving the NHS at younger ages. In 2024, the median age of consultant clinical radiologists leaving the NHS workforce was 50 – down from 56 in 2020. Four in five (79%) of leavers were under 60, and two in five (42%) were under 45. Clinical oncologists followed a similar trend. Their median exit age dropped to 54, from 57 in 2023 and 59 in 2022. Nearly 76% of leavers were under 60, and 26% were under 45. One consultant clinical oncologist told the college that delays in scans and treatment were resulting in missed or late cancer diagnoses. Some patients' conditions were deteriorating or reaching a stage where treatment was no longer possible. Changing Work Practices 'Working conditions and ways of working need to change if we are to address this problem and meet the growing demand for our expertise,' Proctor said. The RCR has called on the government to invest in training and recruitment. In 2024, the NHS spent an estimated £325 million on temporary radiology staff. The cost of outsourcing had doubled since before the COVID-19 pandemic and had surged by almost a quarter in the past year. The RCR estimated that increasing radiology trainee numbers by 50% could eliminate three-quarters of the current shortfall and save the NHS £460 million over the next 10 years. 'Patients are being failed by a chronic lack of radiologists and oncologists,' said RCR president Dr Katharine Halliday. 'The longer we delay action, the worse it gets,' she added.
Yahoo
an hour ago
- Yahoo
GenEditBio Announces First Patient Dosed in Investigator-Initiated Trial of GEB‑101, World's First In Vivo CRISPR-Cas Ribonucleoprotein-Based Genome Editing Investigational Therapy for TGFBI Corneal Dystrophy
HONG KONG, BEIJING and BOSTON, June 6, 2025 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology start-up company focusing on genome editing therapeutic solutions through the discovery of novel and precise Cas nucleases and the development of safe and efficient cargo delivery platforms, today announced a key milestone in the development of its pipeline: First patient has been dosed in an investigator-initiated trial (IIT) of GEB-101, the Company's leading in vivo genome editing program for TGFBI corneal dystrophy. The ongoing IIT is in collaboration with Prof Xingtao ZHOU, MD, PhD, Professor and President, and his team at the Eye & ENT Hospital of Fudan University in Shanghai, China. GEB-101 is a wholly owned program of GenEditBio. Preclinical assessment in non-human primates demonstrated that GEB-101 was well-tolerated after local intrastromal injection and had high safety profile with virtually undetectable off-target effect ( The preclinical research recently received the Excellence in Research Award at the 28th Annual Meeting of the American Society of Gene and Cell Therapy in May 2025 ( The IIT of GEB-101 is an open-label and dose-escalation clinical study to investigate the tolerability of GEB-101 when combined with standard treatment phototherapeutic keratectomy in adults with corneal dystrophy. The first patient, who received GEB-101 in May 2025, has been discharged from the collaborating hospital with no observable adverse event. This trial marks the world's first clinical study of an in vivo CRISPR-Cas ribonucleoprotein (RNP)-based genome editing investigational therapy for TGFBI corneal dystrophy. "Today, on National Sight Day, we are proud and honored to announce that we have initiated the world's first clinical study of an in vivo genome editing investigational therapy for corneal dystrophy. This key milestone represents years of effort in technology platform development and dedication from our world-class research team and clinical partners," said Zongli ZHENG, PhD, Chairman and Co-Founder of GenEditBio, "We stand at the frontier of a new era and recognize the transformative potential of this moment is not just for the Company but for the entire field of genetic medicine because the technology has the potential to extend far beyond corneal dystrophy. Our company is committed to developing fundamentally safe, efficacious and affordable in vivo genome editing therapies for genetic diseases with unmet medical needs". "This investigator-initiated trial marks a defining moment for our award-winning research team and clinical partners. Remarkably, in just one year since initiating our proof-of-concept and preclinical studies, we have successfully integrated our genome editing and delivery technologies to advance this pipeline program from the laboratory to clinical stage, showcasing our competence and dedication to rapidly translate basic research into clinical program to ultimately benefit patients," said Tian ZHU, PhD, CEO and Co-Founder of GenEditBio, "We also express our deepest gratitude to the participant who volunteers in this early stage trial to support medical innovation. As clinical data accumulate, we are positive that GEB-101 has the potential to become a new treatment option for patients with corneal dystrophy". About TGFBI Corneal Dystrophy TGFBI corneal dystrophy is a group of genetic eye disorders caused by mutations in the TGFBI gene, resulting in abnormal protein buildup in the stromal layer of cornea. Symptoms include photophobia, gradual vision loss and recurrent corneal erosions. Current treatment options include phototherapeutic keratectomy and corneal transplantation. These procedures, however, have known limitations such as recurrence and carry risks of sight-threatening complications, underscoring the need for novel therapies. About GEB-101 GEB-101, a wholly owned program of GenEditBio, is a genome editing drug candidate designed as a once-and-done treatment for TGFBI corneal dystrophy. GEB-101 is based on the CRISPR-Cas genome editing technology that targets a particular locus in the mutated TGFBI gene. GEB-101 is encapsulated in the form of RNP in engineered protein delivery vehicle (PDV), a proprietary in vivo delivery system developed by GenEditBio. GEB-101 is to be administered by intrastromal injection and is being investigated for tolerability in the IIT. About GenEditBio Established in 2021 and headquartered in Hong Kong, China, GenEditBio is a gene therapy start-up company with an overarching strategic goal of providing potentially curative, once-and-done and programmable in vivo genome editing-based therapeutic solutions (dubbed "DNA surgery") with high safety profile, unmatched precision, and affordable access for genetic diseases with unmet needs. The Company's core areas of focus include novel Cas nuclease discovery and safe and efficient cargo delivery utilizing lipid nanoparticle (LNP) and engineered protein delivery vehicle (PDV). We have research laboratories and supporting offices in Hong Kong, Beijing, and Boston. GenEditBio is financially backed by top-tier life science investors, including Qiming Venture Partners, Fangyuan Capital, Center Biotherapeutics, Lumosa Therapeutics, HKSTP Venture Fund, and others. For more information, please visit Related Previous Press Releases GenEditBio Scientist Receives Excellence in Research Award at the 28th Annual Meeting of the American Society of Gene and Cell Therapy 2025 GenEditBio to Present Preclinical Data on its Delivery Technology Platform and Drug Pipeline at the 28th Annual Meeting of the American Society of Gene and Cell Therapy Media Contact: Investors Contact: bd@ View original content: SOURCE GenEditBio Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Groups begin lobbying N.S. government over potential booze sale changes
With the provincial government launching consultation on whether to expand sales points for alcohol in Nova Scotia, interested parties are not waiting for a phone call. Organizations on both sides of the issue have started issuing news releases and open letters to Finance Minister John Lohr, whose department is overseeing the process. Lohr announced last week that Infuse Public Relations and Crestview Strategy will collectively manage the public opinion polling of 1,500 random people and stakeholder engagement with 194 groups. The contract for the work is worth $300,000. A news release this week from the Atlantic division of the Canadian Federation of Independent Business said 77 per cent of small businesses in Nova Scotia support allowing convenience stores and grocery stores to sell alcohol. "This moment is the government's chance to support local retailers at a time when over six in 10 are experiencing lower demand, and provide much-needed shelf space to local producers," Duncan Robertson, the federation's director of legislative affairs, said in the release. The CFIB's recommendations include allowing the sale of beverages that do not exceed alcohol by volume of 7.1 per cent in convenience and grocery stores — similar to steps taken in Ontario — and opening those rules to all small businesses, not just large retailers. Nova Scotia already permits alcohol to be sold in some private wine and specialty stores, in on-site stores at breweries and wineries, and farmers' markets. Lohr also received an open letter this week from a group of 14 doctors who specialize in addiction medicine, urging the government not to expand alcohol sales because it would increase consumption and "worsen individual and societal harms." "Every day we care for patients and families suffering from alcohol use disorder and medical complications of alcohol use," the letter said. "Alcohol causes more than 500 deaths, 5,000 hospital admissions, and 35,000 emergency department visits in Nova Scotia each year, and creates more health care and social costs to our province than any other substance." The doctors went on to say that revenue earned through taxation on alcohol sales does not compensate for society-wide costs of health harms, violence and driving accidents attributable to alcohol. They wrote that alcohol is already widely available in Nova Scotia Liquor Corporation retail and agency stores. "It is crucial that the government keeps control of alcohol distribution to minimize further public costs and health harms," they said. Finance Department officials said 194 groups are included in stakeholder engagement so far. That includes 126 craft breweries, wineries and distillers, along with another 11 groups or agencies also in favour of opening things up, such as the Retail Council of Canada. Jim Cormier, the group's Atlantic director of government relations, said members have been looking at this issue particularly since the COVID-19 pandemic. "They've been looking at any way to try and get more people to get away from online shopping, using their smartphones to shop, and get them to come out to go into bricks-and-mortar stores," he said in an interview. Cormier said there can be extended benefits for the local economy by getting people into retail stores where it's possible to cross-promote Nova Scotia craft beer, wine and spirits with other products, such as cheese, berries and glassware. "Obviously it would be more than just Nova Scotia products, but that's the pitch we're making," he said. Council members are looking for things to be as open as possible so there are no winners or losers, said Cormier. "If you're in a rural community and there happens to be a hardware store and they think that they could make a case that they could sell beer and do so in a responsible manner and meet all the rules and regulations, why shouldn't they be allowed to at least apply to do that?" Dr. Kirstin Weerdenburg, a pediatric emergency physician and a trauma team leader at the IWK Health Centre, said it is vital that the government not make any changes without first speaking to the people responsible for caring for those most impacted by alcohol. During her 10 years working in Nova Scotia since moving from Ontario where she also practised medicine, Weerdenburg said she's seen an increase in the number of young people presenting to the emergency department with intoxication. Data needs to be reviewed under the current regulatory regime to understand what's happening before access is expanded, she said. "I do start to get more concerned nowadays, if kids have more access, what their futures will look like." Weerdenburg is also a member of the Nova Scotia Alcohol Policy Coalition, which recently wrote to the government outlining its concerns. The group is one of several dozen representing interests related to health care, intimate partner violence prevention, addictions and marginalized communities slated to be consulted. Although the stakeholder list does not include Nova Scotia Health, the IWK Health Centre or Public Health, a Finance Department spokesperson said the three agencies would be consulted as part of an internal engagement process for government departments. MORE TOP STORIES
